Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736439 | 0.83 | TSHR (0.61) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL29389351 | 0.83 | TSHR (0.61) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL31483487 | 0.81 | TSHR (0.59) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL17110689 | 0.81 | TSHR (0.59) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL18080661 | 0.79 | TSHR (0.58) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL798347 | 0.79 | TSHR (0.58) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL17703980 | 0.79 | TSHR (0.58) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL21104745 | 0.79 | TSHR (0.58) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL14010662 | 0.79 | TSHR (0.58) | TSHRNPSR1RXFP1KMT2ASLC9A1 | |
| SCHEMBL8404027 | 0.79 | TSHR (0.58) | TSHRNPSR1RXFP1KMT2ASLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309738-B2 | Methods for the preparation of thiazolidinethione indene-based chiral auxiliaries | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-11-13 | — | — | US | claimed |
| US-20100179330-A1 | Methods for the Preparation of Thiazolidinethione Indene-Based Chiral Auxiliaries | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | claimed |
| US-4707541-A | Synthesis of hGRF (somatocrinin) in liquid phase and intermediate peptides | SANOFI (FR) | 1987-11-17 | — | — | US | claimed |
| EP-0122818-B1 | LIQUID-PHASE SYNTHESIS OF HPGRF (SOMATOCRININ) AND INTERMEDIATE PEPTIDES | SANOFI S.A. (FR) | 1987-10-07 | — | — | EP | claimed |
| US-4581168-A | COUPLING OF PEPTIDES, THEN HYDROLYSIS | SANOFI (FR) | 1986-04-08 | — | — | US | claimed |
| EP-0171315-A1 | Process for the synthesis of hGRF (Somatocrinin) in the liquid phase, and intermediary peptides | SANOFI S.A. (FR) | 1986-02-12 | — | — | EP | claimed |
| EP-0122818-A1 | Liquid-phase synthesis of hpGRF (Somatocrinin) and intermediate peptides | SANOFI S.A. (FR) | 1984-10-24 | — | — | EP | claimed |
| CN-109715645-B | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, polynucleotide production method, polynucleotide, and bound nucleic acid molecule production method | 日本电气方案创新株式会社 | 2022-03-22 | — | — | CN | disclosed |
| CN-113226332-A | Bivalent targeting conjugates | 阿布特斯生物制药公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-111372928-A | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2020-07-03 | — | — | CN | disclosed |
| US-8309738-B2 | Methods for the preparation of thiazolidinethione indene-based chiral auxiliaries | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2426216-A1 | Prognostic and/or predictive biomarkers and biological applications thereof | Institut Gustave Roussy (IGR) (FR) | 2012-03-07 | — | — | EP | disclosed |
| US-20100179330-A1 | Methods for the Preparation of Thiazolidinethione Indene-Based Chiral Auxiliaries | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1995001353-A1 | ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | CIBA-GEIGY AG (CH) | 1995-01-12 | — | — | WO | disclosed |
| US-5369110-A | Hypotensive agents, cardiac insufficiency treatment | CIBA-GEIGY CORPORATION (US) | 1994-11-29 | — | — | US | disclosed |
| EP-0122818-B1 | LIQUID-PHASE SYNTHESIS OF HPGRF (SOMATOCRININ) AND INTERMEDIATE PEPTIDES | SANOFI S.A. (FR) | 1987-10-07 | — | — | EP | disclosed |
| EP-0171315-A1 | Process for the synthesis of hGRF (Somatocrinin) in the liquid phase, and intermediary peptides | SANOFI S.A. (FR) | 1986-02-12 | — | — | EP | disclosed |
| EP-0122818-A1 | Liquid-phase synthesis of hpGRF (Somatocrinin) and intermediate peptides | SANOFI S.A. (FR) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179330-A1 | Methods for the Preparation of Thiazolidinethione Indene-Based Chiral Auxiliaries | HRH3, TAS1R3, H1-3 | TSHR 170/4885NPSR1 1670/4885RXFP1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.